Sanofi

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris Other stock markets 07:57:30 2024-07-16 am EDT			5-day change	1st Jan Change
92.24 ^EUR	-0.21%		+0.23%	+2.76%

Jul. 12	Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market	RE
Jul. 12	Goldman Sachs, Morgan Stanley Among Banks Lining Up $6.5 Billion Debt Financing for Sanofi Consumer Sale	MT

SANOFI : Credit Suisse remains its Buy rating

January 06, 2023 at 09:21 am EST

Dominic Lunn from Credit Suisse retains his positive opinion on the stock with a Buy rating. Previously set at EUR 106, the target price has been raised to EUR 114.

Latest news about Sanofi

Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market	Jul. 12	RE
Goldman Sachs, Morgan Stanley Among Banks Lining Up $6.5 Billion Debt Financing for Sanofi Consumer Sale	Jul. 12	MT
Banks Including Goldman Sachs, Morgan Stanley Lining Up $6.5 Billion Debt Financing for Sanofi Consumer Sale, Bloomberg Reports	Jul. 12	MT
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices	Jul. 10	RE
Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season	Jul. 10	CI
SANOFI : Receives a Sell rating from Deutsche Bank	Jul. 10	ZD
SANOFI : UBS reiterates its buy recommendation	Jul. 09	CF
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday	Jul. 09	MT
SANOFI : UBS maintains a Buy rating	Jul. 09	ZD
Kymera Reports Expansion of KT-474 Trials; Shares Rise After-Hours	Jul. 08	MT
Kymera Therapeutics, Inc. Announces Expansion of KT-474 HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy	Jul. 08	CI
SANOFI : Jefferies maintains a Buy rating	Jul. 08	ZD
SANOFI : Stifel slightly raises its target on the stock	Jul. 08	CF
That's not so bad, is it?	Jul. 08
Sector Update: Health Care Stocks Steady Premarket Friday	Jul. 05	MT
Sector Update: Health Care	Jul. 05	MT
GlaxoSmithkline Pharmaceuticals Limited Announces Change in Management	Jul. 05	CI
Sanofi's Consumer Health Unit Receives Interest from French State	Jul. 04	MT
Bpifrance eyes investment in Sanofi's consumer health business	Jul. 04	RE
Bain Capital, Cinven, Others Said Mulling Bids for Sanofi's Consumer Health Unit	Jul. 04	MT
Bain, Cinven Explore Joint Bid for Sanofi's Consumer Unit, Bloomberg Reports	Jul. 04	DJ
Paul Hudson, CEO of Sanofi: AI to improve organisational efficiency	Jul. 03	MT
Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division	Jul. 03	MT
Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division	Jul. 03	MT
Bain, Cinven Said to Weigh Joint Bid for Sanofi's Consumer Health Division, Bloomberg Reports	Jul. 03	MT

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release

Related indices

CAC 40 , Euro STOXX 50 Index , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Paul Hudson, CEO of Sanofi: AI to improve organisational efficiency

July 03, 2024 at 04:01 pm EDT

SANOFI : Sanofi’s healthy Q1 performance hailed by markets

April 25, 2024 at 07:58 am EDT

Sanofi : In the hot seat

October 30, 2023 at 06:52 am EDT

More Strategies

Ratings for Sanofi

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

92.43 EUR

Average target price

108.6 EUR

Spread / Average Target

+17.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANOFI	+2.75%	126B
ELI LILLY AND COMPANY	+63.05%	856B
NOVO NORDISK A/S	+38.99%	631B
JOHNSON & JOHNSON	-4.78%	359B
MERCK & CO., INC.	+17.52%	325B
ABBVIE INC.	+8.43%	297B
ASTRAZENECA PLC	+13.42%	244B
ROCHE HOLDING AG	+4.95%	234B
NOVARTIS AG	+16.22%	226B
AMGEN INC.	+14.63%	177B

Other Pharmaceuticals

Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

SANOFI : Credit Suisse remains its Buy rating

Latest news about Sanofi

Chart Sanofi

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Sanofi

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals